RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx is a clinical-stage biopharmaceutical company with a promising drug development and commercialization strategy focused on improving outcomes for cancer patients. With positive progress in both their clinical drug development and commercialization efforts, as well as a new CFO and increasing number of active commercial centers, the company is well-positioned for strong revenue growth in the coming years. Additionally, their unique TAMP therapy platform has the potential to significantly improve the safety and efficacy of cancer treatments. However, risks to the attainment of our price target exist, such as the risks associated with clinical trials, gaining regulatory approvals, and commercializing products.

RenovoRx is facing financial and operational struggles, with a projected loss of $0.35 per diluted share for 2026 and ongoing fundraising efforts to sustain operations. While the potential for their targeted therapy platform is promising, their TIGeR-PaC study is not expected to be completed until mid-2026, with final analysis not triggered until 1H27. Additionally, the company's FDA-cleared medical device has yet to see significant revenue growth and is facing competition in the market. These factors, coupled with potential risks such as failure to gain regulatory approvals and changing economic and healthcare priorities, contribute to the negative outlook on RenovoRx's stock.